Titan Pharmaceuticals (NASDAQ:TTNP) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note published on Wednesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

TTNP opened at $3.56 on Wednesday. The business’s fifty day simple moving average is $4.11 and its 200 day simple moving average is $5.31. Titan Pharmaceuticals has a 52 week low of $3.24 and a 52 week high of $14.80.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.